Gavi Board meeting, 28-29 November 2018

in page functions
Gavi Board Nov 2018

The Gavi Board meeting was held in Geneva, Switzerland on 28-29 November 2018.

Pre-Board briefing sessions


00a - Document list

00b - Agenda


01a - Declarations of interest

01b - Minutes from 6-7 June 2018

01c - No Objection Consent Decisions

01d - Action Sheet


01e - Workplan


03 - 2016-2020 Strategy - Progress Challenges and Risks

04 - Gavi Mid-Term Review (MTR) - No paper

05 - Financial update including forecast

10 - Consent agenda - Committee Charters

10a - Consent agenda - Committee Chair appointments

10b - Consent agenda - Board and Committee member appointments

10c - Consent agenda - Independent Review Committee appointments

10d - Consent agenda - Review of Board Travel Policy

10e - Consent agenda - CEO Authorisation to represent Gavi at IFFIm General Meeting

10f - Consent agenda - Ongoing and planned support for Syria

10g - Consent agenda - Gavi supported measles and rubella immunisation activities - amendment to HSIS support framework

10h - Consent agenda - Post-transition plans for Angola and Timor-Leste and Congo Republic's eligibility for Gavi support

18 - Review of decisions - No paper

19 - Closing remarks and review of Board workplan - No paper

A - Annual report on implementation of the Gender Policy

US$ 80-100 billion

Investing in Gavi’s 2016-2020 strategy has the potential to deliver US$ 80-100 billion in costs averted related to illness, such as productivity loss due to death/disability, treatment costs, caretaker productivity loss and transport costs.

Stack M et al. Estimated economic benefits during Decade of Vaccines, Health Affairs 2011

More facts...

close icon

modal window here